Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes.
Myelodysplastic syndromes (MDS) are clinically heterogeneous, but the presence of specific cytogenetic abnormalities can predict disease manifestations, provide a basis for prognosis, and direct treatment. Conventional cytogenetic analysis is instrumental in identifying chromosomal abnormalities in MDS and novel genetic methods may provide supplementary information. Treatment with lenalidomide was recently shown to be effective in MDS, particularly in those cases with del(5q), resulting in durable cytogenetic remission and hematological responses. In this paradigm, diagnosis of the del(5q) abnormality would be essential to predicting response to therapy.
Olney
Harold J
HJ
Université de Montréal, CHUM Hospital Notre-Dame, 1560 Sherbrooke St E, Montréal, Québec, H2L 4M1, Canada. hj.olney@umontreal.ca
Le Beau
Michelle M
MM
D002869:Chromosome Aberrations; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics*; D006801:Humans; D007621:Karyotyping; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D009364:Neoplasm Recurrence, Local / Q000235:genetics*; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
D013792:Thalidomide; D000077269:Lenalidomide